WANG Yan
Principal Investigator
Dr. Wang Yan, professor, doctoral supervisor. She is deputy director of the Department of Drug Metabolism and Pharmacokinetics, Institute of Materia Medica, Chinese Academy of Medical Sciences, and director of Beijing Key Laboratory of Nonclinical Drug Metabolism and PK/PD Research of Innovative Drugs. She also serves as vice chairperson of the Committee on Drug Metabolism of Chinese Pharmacological Association, vice chairperson of the Committee on Pharmaceutical Analysis of Chinese Pharmaceutical Association, editorial board members of multiple journals.
She is engaged in the research of drug metabolism, pharmacokinetics and drug analysis, focusing on the establishment of key technologies for the interaction between the gut microbiota and natural drugs, and elucidation of metabolic transformation and molecular mechanism based on the gut microbiota. She has led more than 50 projects and participated in 6 new drug development projects, with 14 patents authorized. Dr. Wang has published more than 80 papers, like Signal Transduct Target Ther, Acta Pharm Sin B., Theranostics, Engineering, Metabolism, etc.. These results have exerted a significant influence on the research of gut microbiota and drugs.
1. Oral berberine improves brain dopa/dopamine levels to ameliorate Parkinson's disease by regulating gut microbiota. Signal Transduct Target Ther. 2021, 6(1):1-20.
2. Biotransformation of Timosaponin BII into Seven Characteristic Metabolites by the Gut Microbiota. Molecules . 2021, 24;26(13):3861. doi: 10.3390/molecules26133861.
3. Gut microbiota mediates the absorption of FLZ, a new drug for Parkinson’s disease treatment. Acta Pharm Sin B. 2021, 11(5):1213-1226.
4. The association between intestinal bacteria and allergic diseases—cause or consequence? Front Cell Infect Microbiol. 2021,15;11:650893.
5. Multi-omics analysis provides insight into the possible molecular mechanism of hay fever based on gut microbiota. Engineering. 2021.
6. Determination and application of nineteen monoamines in the gut microbiota targeting phenylalanine, tryptophan, and glutamic acid metabolic pathways. Molecules. 2021, 26 , 1377.
7. Transformation of Berberine to Its Demethylated Metabolites by the CYP51 Enzyme in the Gut Microbiota. J. Pharm. Anal . 2020,14. https://doi.org/10.1016/j.jpha.2020.10.001.
8. Abnormal metabolism of gut microbiota reveals the possible molecular mechanism of nephropathy induced by hyperuricemia. Acta Pharm Sin B. 2020, 10(2):249-261.
9. Transforming of triptolide into characteristic metabolites by the gut microbiota. Molecules. 2020,30;25(3):606.
10. Berberine inhibits adipocyte differentiation, proliferation and adiposity through down-regulating galectin-3. Sci Rep. 2019,16; 9(1):13415.
11. Determination of berberine-upregulated endogenous short-chain fatty acids through derivatization by 2-bromoacetophenone. Anal Bioanal Chem . 2019 ,411(14):3191-3207.
12. Gut microbiota-based pharmacokinetics and the antidepressant mechanism of paeoniflorin. Front Pharmacol. 2019, 10:268.
13. mTOR-dependent upregulation of xCT blocks melanin synthesis and promotes tumorigenesis. Cell Death Differ. 2019,13. doi: 10.1038/s41418-019-0274-0.
14. Gut-brain axis metabolic pathway regulates antidepressant efficacy of albiflorin. Theranostics . 2018,8(21):5945-5959.
15. Berberine induces miR-373 expression in hepatocytes to inactivate hepatic steatosis associated AKT-S6 kinase pathway. Eur J Pharmacol. 2018, 15; 825:107-118.
16. Gut microbiota-regulated pharmacokinetics of berberine and active metabolites in beagle dogs after oral administration. Front Pharmacol. 2018, 9:214.
17. Gut microbiota mediated personalized medicine in berberine treatment. Theranostics . 2017, 7(9):2443-2451.
18. In vitro study of the metabolic characteristics of eight isoquinoline alkaloids from natural plants in rat gut microbiota. Molecules, 2017, 22: 932.
19. Berberine-induced bioactive metabolites of gut microbiota improves energy metabolism. Metabolism. 2017, 70:72–84.
20. Validated quantification method for five ephedrines in dietary supplements using LC–MS/MS: Application to 503 cases. J Chromatogr B Analyt Technol Biomed Life Sci. 2016 Dec 15; 1039:1-7.
21. New potential biomarker for methasterone misuse in human urine by liquid chromatography quadruple time of flight mass spectrometry. Int J Mol Sci. 2016, 17: 4486-4492.
22. The anti-dementia drug candidate, (−)-clausenamide, improves memory impairment through its multi-target effect. Pharmacology & Therapeutics , 2016, 162: 179-187.
23. In vivo metabolite profiling of a purified ellagitannin isolated from Polygonum capitatum in Rats. Molecules , 2016, 21: 1110.
24. Interaction effects on cytochrome P450 both in vitro and in vivo studies by two major bioactive xanthones from Halenia elliptica D. Don. Biomedical Chromatography. 2016, 30: 1953-1962.
25. Simultaneous quantification of ginsenoside Rg1 and its metabolites by high performance liquid chromatography–tandem mass spectrometry: Rg1 excretion in rat bile, urine, and feces. Acta Pharm Sin B. 2016, 6(6):593-599 .
26. Herb–drug interaction between an anti-HIV Chinese herbal SH formula and a tazanavir in vitro and in vivo. J Ethnopharmacol, 2015 Mar 13; 162:369-76.
27. Effect of Berberine on promoting the excretion of cholesterol in high-fat diet-induced hyperlipidemic hamsters. J Transl Med. 2015, 13(1): 278.
28. Efficacy of Berberine in patients with non-alcoholic fatty liver disease. PLoS One. 2015, 10 (8): e0134172.
29. Transforming berberine into its intestine absorbable form by gut microbiota. Sci Rep. 2015, 5: 12155.
30. Metabolism of Chinese Materia Medica in gut microbiota and biological effects. Chinese Herbal Medicines, 2015, 7(2): 109-115.
31. Herb-drug interaction between an anti-HIV Chinese herbal SH formula and Atazanavir in vitro and in vivo. Journal of Ethnopharmacology , 2015, 162(13): 369-376.
32. A small-molecule modulator of the tumor-suppressor mir34a inhibits the growth of hepatocellular carcinoma. Cancer Research , 2014, 74(21): 6236-6247.
33. Biotransformation and in vitro metabolic profile of bioactive extracts from a traditional miao-nationality herbal medicine, Polygonum capitatum. Molecules , 2014, 19: 10291-10308.
34. Metabolite profiling analysis of FR429, an ellagitannin purified from Polygonum capitatum, in rat and human liver microsomes, cytosol and rat primary hepatocytes in vitro. Chemico-Biological Interactions , 2014, 220: 33-40.
35. Kari Germacranes and m-Menthane from Illicium lanceolatum. Molecules , 2014, 19(4): 4326-4337.
36. In vitro identification of cytochrome P450 isoforms responsible for the metabolism of 1-hydroxyl-2, 3, 5-trimethoxy-xanthone purified from Halenia elliptica D. Don. Chemico-Biological Interactions , 2014, 210: 12-19.
37. A potential antitumor ellagitannin, davidiin, inhibited hepatocellular tumor growth by targeting EZH2. Tumor Biology , 2014, 35 (1): 205-212.
38. Tissue distribution of Berberine and its metabolites after oral administration in rats. PLoS One , 2013 Nov, 8(10): e77969. doi:10.1371/journal.pone.0077969.
39. Excretion of berberine and its metabolites in oral administration in rats. Journal of Pharmaceutical Sciences , 2013 Nov, 102(11), 4181-4192.
40. Coumarin derivatives protect against ischemic brain injury in rats. European Journal of Medicinal Chemistry , 2013, Sep., 67, 39-53.
1. Berberine. Editorial board member. Science Press. 2018, Print ISBN: 9787030590381.
2. The Chemistry and Biological Activities of (-)-Clasenamide. Vice editor-in-chief. Chemical Industry Press. 2014, Print ISBN: 9787122206206.
3. Modern research on Chinese herbal medicine. Editorial board member. Peking Union Medical College Press. 2010, Print ISBN: 9787811363548.
4. HPLC analysis of commonly used Chinese herbal medicine. Editorial board member. Science Press. 1999, Print ISBN: 7030070518.
1. 2020, First Prize of the 9th Outstanding Papers Selection Exchange Conference of the Chinese Journal of Pharmaceutical Analysis. Chinese Pharmaceutical Association.
2. 2020, Second Prize of "Acta Pharmaceutica Sinica" Youth Forum Conference. Chinese Pharmaceutical Association.
3. 2019, First Prize of Youth Excellent Paper Award of 2019 Beijing International Symposium on Drug Metabolism. Editorial Department of Acta Pharmaceutica Sinica B .
4. 2019, First prize of Shimadzu Cup, the 14th Outstanding Papers on Pharmaceutical Analysis Selection Exchange Conference of the Chinese Pharmaceutical Journal. Chinese Pharmaceutical Association.
5. 2018, Second Prize of Excellent Papers in 2018 China Pharmaceutical Conference. Chinese Pharmaceutical Association.
6. 2017, First prize of Shimadzu Cup, the 13th Outstanding Papers on Pharmaceutical Analysis Selection Exchange Conference of the Chinese Pharmaceutical Journal. Chinese Pharmaceutical Association.
7. 2017, First Prize of Youth Excellent Paper Award of 2017 Beijing International Symposium on Drug Metabolism. Editorial Department of Acta Pharmaceutica Sinica B.
